Introduction {#s1}
============

Epilepsy, especially drug-refractory epilepsy, with ASD is a chronic neurologic disorder but also places a substantial burden on children, families and society ([@B1]). Previous research reported that the comorbidity rate varied widely, even in large samples including population-based studies, ranging from 2.4 to 63% ([@B2], [@B3]). In different epilepsy syndromes, such as in tuberous sclerosis complex (TSC), the incidence of ASD is 17--63% ([@B4]). In Dravet syndrome (DS), the incidence of ASD is 24--61% ([@B5], [@B6]), and in infantile spasms, it is 35% ([@B7]). Most published studies have primarily focused on clinical characteristics and outcomes of epilepsy with ASD ([@B8]). However, to date, there is still no comprehensive general description of both clinical features and the genetic etiology of these disorders.

In clinical work, we found large heterogeneity in behaviors and outcomes in epilepsy with ASD children, and the reasons are still unclear. In recent years, with whole exome sequencing (WES), neural panel data sequencing, copy number variant (CNV) analysis, and other molecular technologies, increasing numbers of epilepsy with ASD-related diseases have been recognized at the molecular level, such as Angelman syndrome, TSC, Fragile X syndrome, and Rett syndrome. To date, a small number of gene mutations, such as in *SCN1A* and *TSC2*, are known to cause epilepsy and ASD phenotypes simultaneously. Recently, several reviews described epilepsy with ASD genes from the perspectives of bioinformatics and genetics ([@B9]--[@B11]). However, approximately 50% or more of the causes remain unknown. We therefore sought to expand the candidate genes for epilepsy with ASD and determine whether genetically pathogenic patients are more prone to drug-refractory epilepsy, severe ASD, and intellectual disability than non-pathogenic patients. Thus, in the current study, we conducted genetic testing on children with co-occurring epilepsy and ASD to identify causative genetic variants to determine a possible link between genotypes and phenotypes.

Participants and Methods {#s2}
========================

Study Design
------------

Children with epilepsy and ASD were retrospectively recruited from January 1st, 2015, to May 1st, 2018, at the National Children\'s Medical Center, Shanghai, China. Primary data were collected from electronic clinical history systems and medical records from both inpatients and outpatients at the Children\'s Hospital of Fudan University. The key words "autism or ASD and epilepsy or seizure" were used to search the clinical database for patients.

Definitions and Measurements
----------------------------

1.  Epilepsy: (1) Epilepsy was diagnosed based on the International Classification of Diseases−10. Seizure type and epilepsy syndrome were defined according to the criteria of the Commission on Classification and Terminology of the International League Against Epilepsy in 2010. Epilepsy-associated syndrome is considered a well-defined syndrome with an epileptic phenotype in published literature but not a defined epilepsy syndrome by the International League Against Epilepsy.(2) Drug-refractory epilepsy was defined as failure with adequate trials of at least two tolerated, appropriately chosen anti-epileptic schedules to achieve a sustained seizure-free state for \<1 year ([@B12]).

2.  ASD was assessed with the Autism Behavior Checklist, completed by parents, for patients at least 18-month-old with core symptoms of ASD. When the score on the questionnaire was \>61, ASD was considered. Then, all ASD patients were diagnosed by qualified and experienced neurologists and psychologists using the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) published in 2013 and based on the patient\'s clinical behavior. Clinical judgment was based on all available questionnaires including the ADOS (Autism diagnostic observation schedule) and the ADI-R (Autism diagnostic interview-revised). ASD severity was assessed using the DSM-V, which was divided into mild, moderate, or severe ([@B13]).

3.  Intellectual disability (ID) was defined as an IQ lower than 70 with accompanying adaptive behavior deficits. Mild ID was defined as 50 \< IQ ≤ 70, and moderate to severe ID was defined as an IQ \< 50. IQ was acquired using development screening testing, and some of the children took the Wechsler Intelligence Scale.

4.  Brain dysplasia on magnetic resonance imaging (MRI) included hypoplasia in the cerebellar hemispheres and vermis, dysmorphometry of the left and right olfactory bulbs and sulci, abnormalities in the hippocampus and choroid plexus, and malformation of the corpus callosum ([@B14]). The malformations in cortical development were assessed using Barkovich criteria ([@B15]).

Inclusion Criteria
------------------

\(1\) All children aged 1--18 years diagnosed with epilepsy with ASD from January 1st, 2015, to May 1st, 2018, and (2) all subjects followed up at least 1 year after diagnosis and treated with anti-epileptic drugs (AEDs) were included.

Exclusion Criteria
------------------

Children with (1) acute symptomatic epilepsy, including head trauma, brain tumors, and infections of the central nervous system, (2) ASD-like behaviors but failing to meet with DSM-V criteria, or (3) incomplete clinical information or failure to follow-up were excluded.

Ethical Approval
----------------

The study was approved by the Children\'s Hospital of Fudan University ethics committee (NM: (2016) 117). All participants or their parents were made aware of the research and signed written consent forms.

Study Participants and Data Collection
--------------------------------------

All patient medical records were collected, including sex, onset age of seizures and ASD symptoms, seizure types, AEDs used, electroencephalogram (EEG) including sleeping EEG and video EEG, head MRI, family history, perinatal abnormalities, genetic tests, and other neuropsychiatric comorbidities. If data were incomplete, further information was obtained by telephone interview.

Genetic Testing
---------------

Pathogenic copy-number variants were tested using array-based comparative genomic hybridization. Next generation sequencing was used with a targeted neuromuscular gene panel including 2,732 genes or WES. Target ranges were enriched by Agilent (Santa Clara, CA, USA) ClearSeq Inherited Disease panel kits or Agilent SureSelectXT Human All Exon 50-Mb kits and sequenced with an Illumina Hiseq platform. The average sequencing depth of the target region was 100--200×, and the 98% depth of the target sequence reached 20× or more. Both the neuromuscular panel and whole exome sequencing can detect more than 1 Mb copy number abnormalities. If a copy number anomaly was found during the analysis, it was indicated in the report.

Gene variant annotations were referred to using American College of Medical Genetics and Genomics (ACMG) guidelines. According to ACMG guidelines, a variant is considered to be pathogenic when (1) this variant strongly explains the indication for testing and may be responsible for patient phenotype, or (2) the same nucleotide and amino acid change has been reported previously as a pathogenic variant or existed in internal database. A likely pathogenic variant is considered when (1) the variant likely explains the indication for testing and may be responsible for patient phenotype, (2) a *de novo* variant (parent sanger sequencing confirmed) is found in the proband without family history or inherited from the affected parents, (3) regardless of nucleotide change, amino acid change is the same as a previously pathogenic variant, and (4) the null variant, includined g non-sense, frameshift, canonical ± 1 or 2 splice sites, initiation codon, single, or multiexon deletion in a gene, where is considered loss of function According to previous literature ([@B16]). Positive results need to follow Mendel\'s law of inheritance: (1) an autosomal dominant or X-linked dominant gene mutation includinged one heterozygous pathogenic or likely pathogenic variant, (2) an autosomal recessive gene mutation includinged one homozygous or two heterozygous pathogenic or likely pathogenic variants (compound heterozygous), or (3) X-linked recessive genes in male patients including one pathogenic or likely pathogenic variant. All variants were searched in OMIM (<https://www.ncbi.nlm.nih.gov/omim/>) and HGMD (<http://www.hgmd.cf.ac.uk/ac/index.php>) databases to determine pathogenicity.

Statistical Analysis
--------------------

SPSS 20.0 software was used for statistical analyses. Categorical data are presented as counts and percentages and were analyzed with Chi-square test and Fisher\'s exact test and Bonferroni adjustment for multiple analyses as appropriate. Skewed distributions are described with medians and interquartile ranges and were compared by Wilcoxon rank-sum test and Kruskal-Wallis test. Normal distributions were tested by Q-Q analysis, described with means and standard deviations, and compared using Student\'s *t*-tests. A *P-*value \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

We recruited 117 patients using the inclusion and exclusion criteria. Fourteen patients were excluded as follows: four patients did not complete the required information, either due to unsuccessful attempts at the phone interview and/or failure to make contact, three ASD patients had no seizures even though their EEGs were abnormal, six patient had ASD-like symptoms, but the screening scale was negative, and one patient was diagnosed with secondary epilepsy after an upper gastrointestinal hemorrhage. All the patients had an ABC score, eight patients had ADOS scores, three patients had ADI-R scores, and 92 patients met DSM-V criteria. In total, 103 (91.9%) patients were included. Sixty-nine patients suffered epilepsy prior to ASD diagnosis, 28 patients were diagnosed with ASD before epilepsy, and six patients had an unclear relationship between epilepsy and ASD.

[Figure 1](#F1){ref-type="fig"} shows the process from screening to assessment of epilepsy with ASD patients.

![Screening eligibility flow chart.](fneur-10-00505-g0001){#F1}

We first analyzed the demographic and clinical characteristics of epilepsy with ASD patients ([Table 1](#T1){ref-type="table"}). The results show that the ratio of male to female patients was 2.4:1, the median age of seizure onset was 12.0 months \[interquartile range, 7.0\~28.0 months\], and the median age of ASD onset was 24.0 months \[interquartile range, 24.0\~36.0 months\]. Overall, 68.9% (71/103) patients were in seizure remission, while the remainder (31.0%, 32/103) were affected by drug-refractory epilepsy. ID (IQ \< 70, 81.6%) was high in epilepsy with ASD patients, especially moderate to severe ID (IQ \< 50, 58.3%).

###### 

Demographics and clinical features of epilepsy with ASD patients (*n* = 103).

  ------------------------------------------------------------------------------------------------------------------------------------------------
                                                       **Epilepsy with ASD**\   **ASD with epilepsy**\   **Uncertain**\     **Total**\
                                                       ***n* = 69 (%)**         ***n* = 28 (%)**         ***n* = 6 (%)**    ***n* = 103 (%)**
  ---------------------------------------------------- ------------------------ ------------------------ ------------------ ----------------------
  **BASELINE**                                                                                                              

  Male                                                 47 (68.4)                21 (75.0)                5 (83.3)           72 (69.9)

  Age (years) mean ± SD                                5.86 ± 2.90              8.04 ± 3.25              7.82 ± 3.38        6.58 ± 3.16

  **CLINICAL FEATURES**                                                                                                     

  Age of seizure onset (month) Median (IQR)            10 (6.0, 12.0)           47 (36.0, 60.0)          24 (23.0, 27.0)    12.00 (7.00, 30.00)

  **Seizure frequency**                                                                                                     

      Frequently attacks                               55 (79.7)                23 (82.1)                6 (100%)           84 (81.6)

      Infrequently attacks                             14 (20.3)                5 (17.9)                 0 (0)              19 (18.4)

  Status epilepticus                                   16 (23.2)                7 (25.0)                 0 (0)              23 (22.3)

  More than two seizure types                          28 (40.6)                9 (32.1)                 4 (66.7)           41 (39.8)

  **Epilepsy type**                                                                                                         

      Generalized                                      39 (56.5)                19 (67.9)                5 (83.3)           63 (61.2)

      Focal                                            17 (24.6)                6 (21.4)                 1 (16.7)           24 (23.3)

      Combined generalized and focal                   13 (18.8)                3 (10.7)                 0 (0.0)            16 (15.5)

  Duration of seizure (years)                          3.35 (2.0, 4.0)          2.9 (1.62, 3.0)          3.5 (1.75, 5.25)   2.00 (2.00, 4.00)

  Median (IQR)                                                                                                              

  Epilepsy syndrome and epilepsy-associated syndrome   24 (34.8)                8 (28.6)                 0 (0)              32 (31.1)

  **Other psychological comorbidities**                                                                                     

  Attention deficit hyperactivity disorder             11 (15.9)                5 (17.9)                 1 (16.7)           17 (16.5)

  Tic disorder                                         2 (2.9)                  0 (1.0)                  0 (1.0)            2 (1.9)

  Migraine                                             1 (1.4)                  1 (3.8)                  0 (1.0)            3 (2.9)

  Age of ASD onset (month)                             24 (23.25, 36.00)        24 (24.0, 30.0)          24 (24.0, 27.0)    24.00 (24.00, 36.00)

  Median (IQR)                                                                                                              

  ASD symptoms severe after seizure                    13 (18.8)                11 (39.3)                1 (16.7)           25 (24.3)

  **ASD severity**                                                                                                          

      Mild                                             12 (17.4)                2 (7.1)                  3 (50.0)           17 (16.5)

      Moderate                                         32 (46.4)                14 (50.0)                3 (50.0)           49 (47.6)

      Sever                                            25 (36.2)                12 (42.9)                0 (0.0)            37 (35.9)

  **OTHER HISTORY**                                                                                                         

  Perinatal abnormalities                              17 (24.6)                12 (42.9)                0 (0.0)            29 (28.2)

  Family history                                       11 (15.9)                4 (14.3)                 0 (0.0)            15 (14.6)

  **Development history**                                                                                                   

      Normal                                           20 (29.0)                6 (21.4)                 2 (33.3)           28 (27.2)

      Delay                                            49 (71.0)                22 (78.6)                4 (66.7)           75 (72.8)

      Regression                                       32 (47.1)                11 (40.7)                3 (50.0)           46 (45.5)

  Delayed motor development                            48 (69.6)                18 (64.3)                4 (66.7)           70 (68.0)

  Learning disability                                  28 (46.7)                14 (51.9)                1 (16.7)           44 (42.7)

  Unavailable to assess (\<6 years old)                9 (13.0)                 1 (3.6)                  0 (0.0)            9 (8.7)

  **EXAMINATION**                                                                                                           

  **EEG**                                                                                                                   

      No epileptic charge                              19 (27.5)                8 (28.6)                 1 (16.7)           28 (27.2)

      Multifocal charge                                18 (26.1)                4 (14.3)                 1 (16.7)           23 (22.3)

      Focal charge                                     31 (44.9)                16 (57.1)                4 (66.7)           51 (49.5)

      Missing                                          1 (1.4)                  0 (0.0)                  0 (0.0)            1 (0.9)

  **MRI**                                                                                                                   

      Normal                                           28 (40.6)                14 (50.0)                2 (33.3)           44 (42.7)

      Abnormal                                         41 (59.4)                14 (50.0)                4 (66.7)           59 (57.3)

      Brain dysplasia                                  17 (24.6)                6 (21.4)                 1 (16.7)           24 (23.3)

  **Intelligence quotient**                                                                                                 

      IQ \> 70                                         8 (12.3)                 3 (12.0)                 0 (0.0)            11 (10.7)

      50 ≤ IQ ≤ 70                                     12 (18.5)                1 (4.0)                  2 (33.3)           15 (14.6)

      IQ \< 50                                         45 (69.2)                21 (84.0)                4 (66.7)           67 (67.0)

      Missing                                          5 (7.2)                  3 (10.7)                 0 (0.0)            8 (7.8)

  **Genetic testing**                                                                                                       

      Positive                                         24 (34.8)                15 (53.6)                2 (33.3)           47 (45.6)

      Negative                                         37 (53.6)                8 (28.6)                 2 (33.3)           41 (39.8)

      No testing                                       8 (11.6)                 5 (17.9)                 2 (33.3)           15 (14.5)

  **TREATMENT**                                                                                                             

  **AEDs used**                                                                                                             

      No AED                                           2 (2.9)                  8 (28.6)                 0 (0.0)            10 (9.7)

      Monotherapy                                      29 (42.0)                6 (21.4)                 3 (50.0)           38 (36.8)

      Polytherapy                                      38 (55.1)                14 (50.0)                3 (50.0)           55 (53.4)

  Seizure-controlled epilepsy                          45 (65.2)                20 (71.4)                6 (100.0)          71 (68.9)

  Refractory epilepsy                                  24 (34.8)                8 (28.6)                 0 (0.0)            32 (31.1)
  ------------------------------------------------------------------------------------------------------------------------------------------------

*ASD, autism spectrum disorder; MRI, magnetic resonance imagine; EEG, electroencephalogram; IQ, intelligence quotient; AEDs, antiepileptic drugs*.

We found that 31.1% patients (32/103) were diagnosed with epilepsy syndrome and epilepsy-associated syndromes, the details of which are shown in [Figure 2](#F2){ref-type="fig"}. Rett syndrome and DS were common in patients (21.8%, 7/32). It should be noted that two of the Rett syndrome patients were diagnosed using clinical criteria, but no variants were identified, and the remainder had clear *MECP2 de novo* gene mutations.

![Epilepsy syndrome and epilepsy-associated syndromes in epilepsy with ASD patients. GEFS+, Generalized epilepsy with febrile seizures plus; TSC, tuberous sclerosis complex; LKS, Landau-Kleffner syndrome; LGS, Lennox-Gastaut syndrome; CAE, childhood absence epilepsy; SWS, Sturge-Weber syndrome.](fneur-10-00505-g0002){#F2}

Genetic Characteristics of Epilepsy With ASD Patients
-----------------------------------------------------

Eighty (88/103, 85.4%) patients received genetic testing, five patients had CNV analysis, 14 patients had targeted neuromuscular panel results, 61 patients had WES results, seven patients had WES and CNV results, and one patient and CNV and targeted panel results. In all, 53.9% (47/88) were positive for gene mutations and CNVs ([Table S1](#SM1){ref-type="supplementary-material"}). Gene mutations, involving 25 kinds of genes, were the most common etiological cause and accounted for 83.0% (39/47) of co-occurring epilepsy with ASD patients, with *de novo* mutations accounting for 46.8% (22/47) of patients. Among these genes, *SCN1A* (14.9%, 7/47) was most frequently associated with epilepsy syndromes, such as DS and general febrile seizures (FS). *MECP2* (10.6%, 5/47) was the second most frequent and was associated with Rett syndrome. In our study, of the 5 CNV-negative cases, two patients were negative for WES, two patients could not be contacted, and one patient refused WES.

Next, we performed an enrichment analysis of positive genes and categorized them into eight subtypes based on molecular functions as seen in [Figure 3](#F3){ref-type="fig"}. Results indicated that voltage-gated ion channel activity genes played an important role in epilepsy with ASD patients, including *SCN1A, SCN2A, CACNA1A, CACNA1H, CACNA1D*, and *KCNQ2* (*P* \< 0.05), which were as further classified as sodium ion channel genes, calcium ion channel genes, and potassium ion channel genes (detailed information in [Table S2](#SM2){ref-type="supplementary-material"}).

![The top eight molecular function classifications of epilepsy with ASD pathogenic genes. Voltage-gated ion channel activity included *CACNA1A, SCN1A, CACNA1H, SCN2A, CACNA1D*, and *KCNQ2*. Extracellular ligand-gated ion channel activity included *GABRG2*. Methyltransferase activity included *EHMT1*. Cell adhesion molecular activity included *CNTNAP2* and *PCDH19*. Serine-type peptidase activity included *TPP1*. ATPase activity included *DYNC1H1*. Structural constituents of the cytoskeleton included *NF2*, and transferase activity included *PIGA*.](fneur-10-00505-g0003){#F3}

The causative variants in 25 genes and eight CNVs were annotated individually for the genotype and phenotype correlations. These variants were classified into three categories, epilepsy, epilepsy with ASD, and ASD, based on published data ([Figure 4](#F4){ref-type="fig"}). The results showed 18 causative variants overlapped in epilepsy and ASD, accounting for 54.5% (18/33) of the examined genes.

![Pathogenic variant category based on reported phenotypes from PubMed, OMIM, and GeneReviews database searches. Epilepsy and ASD have a large overlap in etiology.](fneur-10-00505-g0004){#F4}

Differences Between the Positive Genetic Test Group and the Negative Genetic Test Group
---------------------------------------------------------------------------------------

Comparative analysis of the positive genetic test group and negative genetic test group is shown in [Table 2](#T2){ref-type="table"}. The results showed that epilepsy with ASD patients who tested positive for genetic abnormalities were prone to higher rates of epilepsy syndrome and epilepsy-associated syndromes (corrected *P* = 0.014). Age of seizure onset was earlier in the positive test group than in the negative test group (corrected *P* = 0.048). The number of AEDs used was higher in the positive test group than in the negative test group (*P* = 0.01). ASD severity, intellectual disability, and other variables were not significantly different ([Table 2](#T2){ref-type="table"}).

###### 

Comparison of clinical characteristics between the positive genetic test group and the negative genetic test group (*n* = 88).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variables**                                            **Positive genetic test group**\   **Negative genetic test group**\   ***P-*value**   ***P-*value-corrected[^\*^](#TN1){ref-type="table-fn"}**
                                                           **(*n* = 47)**                     **(*n* = 41)**                                     
  -------------------------------------------------------- ---------------------------------- ---------------------------------- --------------- ----------------------------------------------------------
  Male (%)                                                 31 (66.0)                          28 (68.3)                          0.816           0.996

  **Age of seizure onset (month)**\                        **12.0 (6.0, 18.0)**               **12.0 (10.5, 36.0)**              **0.021**       **0.048**
  **Median (IQR)**                                                                                                                               

  Age of ASD onset (month)\                                24.0 (24.0, 36.0)                  24.0 (20.0, 36.0)                  0.481           0.481
  Median (IQR)                                                                                                                                   

  More than 2 seizure types                                22 (45.8)                          14 (34.1)                          0.228           0.323

  Epilepsy type                                                                                                                  0.423           

      Generalized                                          26 (55.3)                          27 (65.9)                                          

      Focal                                                12 (25.5)                          10 (24.4)                                          

      Combined generalized and focal                       9 (19.1)                           4 (9.8)                                            

  Status epilepsy                                          10 (21.3)                          8 (19.5)                           0.838           1.000

  **Epilepsy syndrome and epilepsy-associated syndrome**   **22 (46.8)**                      **8 (19.5)**                       **0.007**       **0.014**

  ASD symptoms severe after seizure                        22 (46.8)                          16 (41.0)                          0.591           0.749

  MRI abnormal                                             26 (55.3)                          24 (58.5)                          0.761           0.930

  Cerebral dysplasia in MRI                                10 (21.3)                          9 (22.0)                           0.939           1.000

  Multifocal charge in EEG                                 11 (23.4)                          9/40 (22.5)                        0.557           

  Focal charge in EEG                                      26 (53.2)                          21/40 (51.2)                       0.559           

  Intelligence quotient                                                                                                          0.707           

      IQ \> 70                                             6 (13.0)                           4 (10.0)                                           

      50 ≤ IQ ≤ 70                                         8 (17.4)                           5 (12.5)                                           

      IQ \< 50                                             32 (69.6)                          31 (77.5)                                          

  Motor delay                                              35 (74.5)                          25 (61.0)                          0.175           0.260

  ASD severity                                                                                                                   0.504           

      Mild                                                 5 (10.6)                           8 (19.5)                                           

      Moderate                                             23 (48.9)                          18 (43.9)                                          

      Severe                                               19 (40.4)                          15 (36.6)                                          

  **Number of AEDs used mean ± SD**                        **2.06 ± 1.09**                    **1.46 ± 1.02**                    **0.010**       

  Refractory epilepsy                                      19 (40.4)                          9 (22.0)                           0.063           0.104
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ASD, autism spectrum disorder; MRI, magnetic resonance imagine; EEG, electroencephalogram; IQ, intelligence quotient; AEDs, antiepileptic drugs. bold values mean P \< 0.05*.

*Adjusted for multiple testing using Bonferroni-adjustment*.

Gene Distribution in the Seizure-Controlled Group and the Drug-Refractory Epilepsy Group
----------------------------------------------------------------------------------------

We next analyzed the gene distribution of the two groups and found that *MECP2* mutations were most prominent in the seizure-controlled group (13.7%, 4/29), and *SCN1A* mutations were most prominent in the drug-refractory epilepsy group (31.5%, 6/19) ([Figure 5](#F5){ref-type="fig"}).

![Causative variants in the seizure-controlled group and the refractory group. **(A)** Shows that *MECP2* is the primary gene mutated in the seizure-controlled epilepsy with ASD group, while CNV abnormalities in the seizure-controlled group include 2p 13.2 deletion, 16p 11.2 deletion, 16p 13.11 duplication, 17p 12 deletion, and 22q13.2 deletion. **(B)** Shows that *SCN1A* is the primary gene mutated in the refractory epilepsy with ASD group, while CNV abnormalities in the refractory group include 7q 11.23 duplication, X chromosomal duplication, and 15q 11.3 duplication.](fneur-10-00505-g0005){#F5}

Discussion {#s4}
==========

Epilepsy and ASD patients have a definite overlap in clinical behavior and etiology, which demonstrates the neural network specificity of the two diseases. Understanding this peculiarity is expected to provide a window for exploring the shared mechanism of these neurodevelopmental disorders. This study provides a genetic spectrum and comprehensive clinical analysis of epilepsy with ASD patients in China. Furthermore, this study provides insight into the possible etiology of these disorders based on genetic molecular function.

Epilepsy with ASD is a group of highly heterogeneous diseases with diverse phenotypes and genotypes and with various comorbidity rates for different epilepsy syndromes. In the current study, Rett syndrome, which is characterized by developmental regression, ASD-like symptoms, and epilepsy and has a higher incidence in females, was the disease most associated with the experimental cohort. Similarly, DS was common in epilepsy with ASD patients due to *SCN1A* gene mutations. The above results were in accordance with previous studies ([@B17], [@B18]). We also found that *SCN1A* mutations were associated with FS, generalized epilepsy with FS plus (GEFS+), and DS. Among these diseases, FS and GEFS+ tend to have benign outcomes, and seizures are easy to control. However, DS is defined as intractable epileptic encephalopathy and usually has poor prognosis.

In the present study, the proportion of patients with drug-refractory epilepsy with ASD was 31.1%, which is close to the reported incidence of drug-refractory epilepsy in the general population with epilepsy (36.7%) ([@B19]). However, we are unable to conclude whether seizures are better or worse controlled in epilepsy with ASD without comparative studies involving epilepsy alone. In our study, although no statistical significance was found, drug-refractory epilepsy showed a trend of increased incidence in the positive genetic test group compared with the negative genetic test group, which was likely because drug-refractory epilepsy was more likely have a genetic etiology, such as has been reported for *PCDH19* ([@B20]) and *SCN1A* gene mutations ([@B21]), which carry a greater risk of drug-refractory epilepsy. The result may be associated with the small sample size used in the study. Epilepsy and ASD often cooccur with varying degrees of developmental delay, intellectual and learning disabilities, and behavioral problems ([@B22]). Although we tried to accurately collect both ASD age onset and age of diagnosis (if different), we found it difficult to identify specific ages because ASD symptoms might occur earlier than is normally recognized by either parents or teachers.

In a large population-based cohort study, ASD patients with an IQ \<70 had a 5-fold increased risk for epilepsy compared with patients with an IQ \> 70 ([@B2]). Although most studies showed an increased risk of intellectual disability ([@B23]), our study indicated no association between ID severity and drug-refractory epilepsy. Similarly, we found that the degree of ID was not directly associated with increases in seizures. He et al. ([@B24]) showed that there was no difference in ID severity between LGS and DS. We therefore speculated that ID might not account for the poor outcomes of epilepsy with ASD patients, as ID, especially moderate to severe ID, was common in both groups.

The current study reinforces the importance of genetic testing for clarifying the etiology and prognosis of epilepsy with ASD patients. From our study, the clinical genetic testing strategy for both epilepsy and ASD were similar to those previously reported ([@B11]). First, we used a chromosomal microarray followed by targeted next-generation sequence (NGS) gene panels to determine if possible positive results were evident, after which we used WES. If the parents have another child, we recommend trio-WES, which is conducive to prenatal counseling. NGS sequencing and bioinformatics analysis can simultaneously detect pathogenic variants and copy number variants (\>1 Mb). The analysis process includes interpretation of large fragment chromosomal copy number variants. For negative results, due to the limitations of current research methods, it is not possible to completely rule out certain variants, and there may be other types of genetic mutations or non-genetic factors that are difficult to detect and cannot be determined. In fact, to avoid false negative results, children in this study underwent at least one genetic testing method with the informed consent of the guardians, especially when their parents wanted to have a second child.

Although the causal relationship between epilepsy and ASD is not clear, there is a large overlap between the pathogenic genes among the two (52.9%), as seen in [Figure 3](#F3){ref-type="fig"}. Among the genes associated with epileptic encephalopathy in infancy and childhood, 62 genes were associated with epileptic encephalopathy, and as many as 34 genes were candidates for ASD ([@B25]). In our study, more than half the patients were positive for genetic testing, and *de novo* genes played an important role in etiology. Through summary analysis of the positive results, we found that ion channel genes accounted for a relatively high proportion, especially those associated with sodium ion channels. The results agree with previous studies on the etiology of epilepsy ([@B26]). Specifically, we found the top two most frequently mutated genes to be *SCN1A* and *MECP2*. It has been reported that mutation of *SCN1A* is the most common mutation associated with epilepsy in the clinic ([@B20]), especially *de novo* mutations in drug-refractory epilepsy ([@B27]). Several reviews have analyzed and summarized gene mutations in epilepsy and ASD and indicated a common overlap between mutated genes and the respective diseases ([@B28]). Our findings strengthen evidence for these previous observations. Therefore, we believe there is a strong indication for genetic testing for children with epilepsy and ASD as the results of these tests will likely lead to better diagnosis, more precise treatment, and more accurate prognosis assessment. The results of this study also point to the significance of screening for ASD patients with ion channel genetic mutations related to epilepsy, which may help reduce the rate of missed and delayed diagnosis. In the current study, 15 patients failed to undergo genetic testing for a variety of reasons, including that patients were seizure-free or were easily able to control seizures using AEDs and determined that either it was unnecessary to spend a large sum of money on genetic testing or that WES was too expensive.

The study had several limitations. First, because it was a retrospective study and because a small portion of patients were examined in other hospitals, we failed to collect all the necessary information from patients. Even though best efforts were made, especially for IQ test results, EEG results, and brain MRI scans. Second, as this study was an observational cohort study, we are not able to make statements about causal relationships in epilepsy and ASD. Third, the sample size was too limited to obtain a definitive conclusion, and therefore, a large multicenter cohort study is needed. Finally, the study lacked an ASD specific diagnostic instrument for most ASD patients. All ASD children were recommended for ADOS or ADI-R assessment after clinical diagnosis, but most ASD families refused to participate in because of the long waiting period (which may take about 6 months). They were more eager to go to rehabilitation institutions for language training and behavioral interventions as soon as possible.

However, to the best of our knowledge, this study is the first general, descriptive study of a combination of clinical and genetic characteristics in an epilepsy with ASD population without epilepsy syndrome. Our research enlarged the overlapping gene spectrum by summarizing phenotypes and genotypes. According to the latest review ([@B29]), 14 types of genes associated with cooccurring epilepsy and ASD were summarized. This study further expanded the gene profile and added calcium channel genes, such as *CACNA1A* and *CACNA1D*, that had been reported in some cases but not classified yet. In addition, this study was a comprehensive, multidimensional, multiphenotype study that characterized the clinical features of epilepsy with ASD patients.

Conclusions {#s5}
===========

In ASD patients with epilepsy, almost half of the patients have a genetic etiology. Among them, *SCN1A* and *MECP2* are responsible for most of the phenotypes associated with these respective disorders. ASD patients with epilepsy are more susceptible to epilepsy syndrome and epilepsy-associated syndrome. There were no differences between intractable seizures, ASD severity, or the degree of ID in etiology-known patients and etiology-unknown patients, and as such, future population-based, multicenter, prospective studies are needed to further confirm the results of the current study. Genetic testing is very important for epilepsy and ASD patients because it may be helpful for pediatricians to determine proper treatment and prognosis evaluation. Finally, in clinical work, it is highly desirable to perform ASD screening for children with epilepsy with ion channel gene mutations.
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